Twist Bioscience (NASDAQ:TWST) Stock Price Down 5.4% - What's Next?

Key Points

• Twist Bioscience's stock declined by 5.4% during trading on Tuesday, closing at $24.83, with significant lower trading volume compared to average.
• The company reported a quarterly earnings per share (EPS) of (0.47), exceeding expectations, and has a consensus target price of $49.40 from analysts.
• Insider selling occurred recently, with CEO Emily M. Leproust and CFO Adam Laponis selling a total of 5,250 shares, while institutional investors have been increasing their stakes in the company.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) shares were down 5.4% on Tuesday . The company traded as low as $24.44 and last traded at $24.83. Approximately 486,227 shares were traded during trading, a decline of 59% from the average daily volume of 1,194,919 shares. The stock had previously closed at $26.25.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TWST shares. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a report on Monday, August 4th. Cowen restated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $49.40.

Twist Bioscience Stock Performance

The company has a market cap of $1.53 billion, a PE ratio of -17.46 and a beta of 2.31. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The firm's 50-day simple moving average is $30.52 and its two-hundred day simple moving average is $34.21.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The company had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the sale, the chief financial officer directly owned 103,569 shares in the company, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 2,265 shares of Twist Bioscience stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $25.76, for a total transaction of $58,346.40. Following the sale, the chief executive officer owned 634,740 shares of the company's stock, valued at approximately $16,350,902.40. The trade was a 0.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,911 shares of company stock valued at $288,159. Company insiders own 3.01% of the company's stock.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently made changes to their positions in the company. Osaic Holdings Inc. lifted its stake in shares of Twist Bioscience by 31.6% in the 2nd quarter. Osaic Holdings Inc. now owns 7,054 shares of the company's stock valued at $261,000 after purchasing an additional 1,694 shares during the period. Squarepoint Ops LLC raised its position in Twist Bioscience by 192.8% during the second quarter. Squarepoint Ops LLC now owns 71,708 shares of the company's stock worth $2,638,000 after acquiring an additional 47,221 shares during the period. Geneos Wealth Management Inc. acquired a new position in Twist Bioscience during the second quarter worth $97,000. Soleus Capital Management L.P. acquired a new position in Twist Bioscience during the second quarter worth $13,038,000. Finally, Man Group plc raised its position in Twist Bioscience by 5.3% during the second quarter. Man Group plc now owns 106,509 shares of the company's stock worth $3,918,000 after acquiring an additional 5,348 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.